The presence of tumoural PD-L1-positive TILs correlates with adverse clinic-pathological features and basal and HER2 breast cancer, but interestingly also with clinical response to PD-1 pathway blockade with anti-PD1 or anti PD-L1 targeted immunotherapy [100, 101]. This evidence concerns the gene CD274 and breast carcinoma.